OPRX · CIK 1448431
What OptimizeRx Corp. told the SEC could break it.
OptimizeRx is concentrated at both ends of its pharma-marketing business. On the customer side, despite serving 100-plus pharma manufacturers, its top five were about 47% of 2025 revenue with three individual customers each exceeding 10%; on the delivery side it's even more concentrated, with 62% of revenue flowing through just its two largest eRx/EHR channel partners, so losing one would materially hurt the business. Its demand ultimately rides on pharma marketing budgets, which are exposed to regulation — FDA reforms of direct-to-consumer advertising, most-favored-nation drug-pricing rules that could squeeze budgets, and indirect exposure to anti-kickback and false-claims laws.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Customer concentration
- Top-5 customers ~47% of revenue; three customers each >10%high
Despite 100+ pharma-manufacturer customers, the top five were ~47% of revenue in 2025 and three individual customers each exceeded 10% (13.2%, 11.3%, 10.0%), so losing a large customer or pharma brand would materially hurt results.
“Our top five customers represented approximately 47% and 49% of our revenue for the years ended December 31, 2025 and 2024, respectively. In 2025 and 2024, we had three customers and two customers, respectively, that represented more than 10% of our revenues.”
SEC filing →As of 2026
Supplier concentration
- Two largest eRx/EHR channel partners = 62% of revenuehigh
OptimizeRx delivers a large share of its messaging through eRx/EHR channel partners; 62% of 2025 revenue (57% in 2024) was generated through its two largest channel partners, so losing one would materially harm the business.
“We generated 62% and 57% of our revenue through our two largest channel partners in 2025 and 2024, respectively. As such, the inability to maintain one or more of these relationships could materially adversely impact our business.”
SEC filing →As of 2026
Regulatory & policy
- Pharma DTC-marketing regulation (FDA reforms), drug-pricing (MFN), anti-kickback/false-claims lawsmedium
Demand depends on pharma marketing budgets, which are exposed to FDA reforms of direct-to-consumer advertising, MFN drug-pricing rules that could cut drug prices/budgets, and indirect exposure to anti-kickback/false-claims laws.
“The current U.S. administration, the U.S. Department of Health and Human Services (“HHS”) and the U.S. Food and Drug Administration (“FDA”) have recently announced an initiative intended to ensure transparency and accuracy in direct-to-consumer pharmaceutical advertisements through a series of reforms that have included and are expected to continue to include FDA rulemaking, additional enforcement action”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch